Leponex (Clozapine)

Leponex, an atypical antipsychotic, is used within the schizophrenia and mood‑disorder therapeutic area.

• Treatment‑resistant schizophrenia: reduces psychotic symptoms in patients who have not responded to other antipsychotics.
• Schizoaffective disorder: helps control both mood and psychotic features.
• Reduction of suicidal behavior in schizophrenia: lowers the risk of suicide in patients with schizophrenia.

• Clozapine acts primarily as an antagonist at dopamine D2 receptors and serotonin 5‑HT2A receptors, while also modulating activity at D4, 5‑HT2C, muscarinic, adrenergic and histamine receptors. This broad receptor profile leads to decreased dopaminergic transmission in mesolimbic pathways and enhanced serotonergic activity, contributing to its efficacy in refractory psychosis and mood stabilization.

Leponex may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Sedation: drowsiness or feeling unusually sleepy.
• Weight gain: increase in body weight over time.
• Constipation: reduced bowel movements or difficulty passing stool.
• Drooling (sialorrhea): excess salivation, especially at night.
• Tachycardia: faster than normal heart rate.

Serious or Rare Side Effects

• Agranulocytosis: severe drop in white blood cells that can lead to infection.
• Myocarditis: inflammation of the heart muscle, potentially life‑threatening.
• Seizures: risk increases with higher plasma concentrations.
• Neuroleptic malignant syndrome: rare but critical reaction with fever, rigidity, and autonomic instability.

Before initiating Leponex, clinicians should consider several safety measures.

• Blood monitoring: perform regular white‑blood‑cell counts to detect agranulocytosis early.
• Cardiac assessment: evaluate for myocarditis before and during therapy.
• Seizure risk: avoid or use cautiously in patients with uncontrolled epilepsy.
• Metabolic monitoring: check weight, glucose and lipid levels periodically.
• Drug interactions: review concomitant medications for CYP1A2 inhibitors or inducers.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Clozapine interacts with several medicines that can alter its safety or effectiveness.

Major Interactions (Avoid)

• CYP1A2 inhibitors (e.g., fluvoxamine): can raise clozapine plasma levels and increase toxicity.
• Concomitant use with drugs that cause agranulocytosis (e.g., carbamazepine): heightens risk of severe neutropenia.
• Benzodiazepines combined with clozapine: may lead to excessive sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• CYP1A2 inducers (e.g., smoking, carbamazepine): may lower clozapine concentrations and reduce efficacy.
• Anticholinergic agents: can worsen constipation already associated with clozapine.
• Lithium: may increase the likelihood of seizures when used together.